Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6291-6297

  Saleh Mghir, Azzam ^a,b   Dumitrescu, Oana ^c   Dinh, Aurélien ^a,b   Boutrad, Yassine ^a,b   Massias, Laurent ^d   Martin, Émilie ^c   Vandenesch, François ^c   Etienne, Jérôme ^c   Lina, Gérard ^c   Creḿieux, Anne Claude ^a,b  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c UNIVERSITÉ LYON 1   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; PANTON VALENTINE LEUKOCIDIN; RIFAMPICIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; COMMUNITY ASSOCIATED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; COMMUNITY-ACQUIRED INFECTIONS; EXOTOXINS; FEMALE; LEUKOCIDINS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUTATION; OSTEOMYELITIS; RABBITS; RIFAMPIN;

EID: 84869232567     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00926-12     Document Type: Article

References (45)

1. Badiou C, et al. 2008. Panton-Valentine leukocidin is expressed at toxic levels in human skin abscesses. Clin. Microbiol. Infect. 14:1180-1183.
2. Bocchini CE, et al. 2006. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 117:433-440.
3. Centers for Disease Control and Prevention. 2007. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza - Louisiana and Georgia, December 2006-January 2007. MMWR Morb. Mortal. Wkly. Rep. 56:325-329.
4. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. 2011. Antimicrobial resistance: not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin. Infect. Dis. 52:99-114.
5. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S14. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Crémieux AC, et al. 2009. Panton-Valentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS One 4:e7204. doi:10.1371/journal.pone.0007204.
7. Davies TA, et al. 2007. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:2621-2624.
8. Deleo FR, Otto M, Kreiswirth BN, Chambers HF. 2010. Community-associated methicillin-resistant Staphylococcus aureus. Lancet 375:1557-1568.
9. Dohin B, et al. 2007. Pediatric bone and joint infections caused by Panton-Valentine leukocidin-positive Staphylococcus aureus. Pediatr. Infect. Dis. J. 26:1042-1048.
10. Dumitrescu O, et al. 2007. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob. Agents Chemother. 51:1515-1519.
11. Dumitrescu O, et al. 2011. Beta-lactams interfering with PBP1 induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus. Antimicrob. Agents Chemother. 55:3261-3271.
12. Enright M, Day N, Davies C, Peacock S, Spratt B. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008-1015.
13. Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
14. Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. 2009. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin. Infect. Dis. 49:65-71.
15. Gillet Y, et al. 2002. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753-759.
16. Gonzalez BE, et al. 2005. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 115:642-648.
17. Harmsen D, et al. 2003. Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J. Clin. Microbiol. 41:5442-5448.
18. Jacqueline C, et al. 2010. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J. Antimicrob. Chemother. 65:1749-1752.
19. Jacqueline C, et al. 2007. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51:3397-3400.
20. Jarraud S, et al. 2002. Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect. Immun. 70:631-641.
21. John AK, et al. 2009. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob. Agents Chemother. 53:2719-2724.
22. Kaplan SL. 2010. Acute hematogenous osteomyelitis in children: differences in clinical manifestations and management. Pediatr. Infect. Dis. J. 12:1128-1129.
23. Leonard SN, Cheung CM, Rybak MJ. 2008. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2974-2976.
24. Lin G, Appelbaum PC. 2008. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. Diagn. Microbiol. Infect. Dis. 60:233-235.
25. Liu C, et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292.
26. Moisan H, Pruneau M, Malouin F. 2010. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J. Antimicrob. Chemother. 65:713-716.
27. Murthy B, Schmitt-Hoffmann A. 2008. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin. Pharmacokinet. 47:21-33.
28. Narita S, et al. 2001. Phage conversion of Panton-Valentine leukocidin in Staphylococcus aureus: molecular analysis of a PVL-converting phage, phiSLT. Gene 268:195-206.
29. Noel GJ, et al. 2008. Results of a double-blind randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob. Agents Chemother. 52:37-44.
30. Norden CW. 1970. Experimental osteomyelitis. I. A description of the model. J. Infect. Dis. 122:410-418.
31. Panton PN, Valentine FCO. 1932. Staphylococcal toxin. Lancet i:506-508.
32. Proctor RA. 2008. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 46:584-593.
33. Saleh-Mghir A, et al. 2002. Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob. Agents Chemother. 46:1122-1124.
34. 14C]teicoplanin in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob. Agents Chemother. 42:2830-2835.
35. Saleh-Mghir A, et al. 2011. Panton-Valentin leukocidin (PVL) increases hematogenous lung lesions but not mortality of severe sepsis associated with community associated methicillin-resistant Staphylococcus aureus (CA-MRSA) rabbit acute osteomyelitis (AOM), abstr. B-054. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother.
36. Saleh-Mghir A, et al. 2011. Ceftobiprole efficacy in vitro on Panton- Valentine leukocidin production and in vivo in a rabbit community-associated methicillin-resistant Staphylococcus aureus osteomyelitis model, poster P-1068. 21st Eur. Congr. Clin. Microbiol. Infect. Dis.-27th Int. Congr. Chemother.
37. Stryjewski ME, et al. 2007. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 44:190-196.
38. Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. 2010. Ceftobiprole is superior tovancomycin,daptomycin,andlinezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:610-613.
39. Tseng CW, et al. 2009. Staphylococcus aureus Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury. PLoS One 4:e6387. doi:10.1371/journal.pone.0006387.
40. Vander Have KL, et al. 2009. Community-associated methicillin-resistant Staphylococcus aureus in acute musculoskeletal infection in children: a game changer. J. Pediatr. Orthop. 29:927-931.
41. Vergidis P, et al. 2011. Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. Antimicrob. Agents Chemother. 55:1182-1186.
42. Voyich J, et al. 2006. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J. Infect. Dis. 194:1761-1770.
43. Yin LY, Calhoun JH, Thomas JK, Shapiro S, Schmitt-Hoffmann A. 2008. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1618-1622.
44. Yun HC, Ellis MW, Jorgensen JH. 2007. Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees. Diagn. Microbiol. Infect. Dis. 59:463-466.
45. Zimmerli W, Trampuz A, Ochsner PE. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.